Literature DB >> 21371719

A novel exon 3 mutation in a Tunisian patient with Lafora's disease.

H Mrabet Khiari1, G Lesca, A Malafosse, A Mrabet.   

Abstract

We report a Tunisian patient born from consanguineous marriage affected with progressive myoclonus epilepsy and cognitive decline, consistent with the diagnosis of Lafora disease. Genetic analysis showed a novel c.659 T>A mutation on exon 3 of the EPM2A gene, converting a leucine to a glutamine residue at amino acid position 220 (p.Leu220Gln), in the dual-specificity phosphatase domain.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371719     DOI: 10.1016/j.jns.2011.02.011

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

Review 1.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

2.  Epilepsy genetics in Africa: challenges and future perspectives.

Authors:  Guida Landouré; Youssoufa Maiga; Oumar Samassékou; Karamoko Nimaga; Mahamadou Traoré; Kenneth H Fischbeck
Journal:  North Afr Middle East Epilepsy J       Date:  2014 Sep-Oct

3.  Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.

Authors:  Luca Vignatelli; Francesca Bisulli; Federica Pondrelli; Lorenzo Muccioli; Laura Licchetta; Barbara Mostacci; Corrado Zenesini; Paolo Tinuper
Journal:  Orphanet J Rare Dis       Date:  2021-08-16       Impact factor: 4.123

4.  Spectrum of Genetic Diseases in Tunisia: Current Situation and Main Milestones Achieved.

Authors:  Nessrine Mezzi; Olfa Messaoud; Rahma Mkaouar; Nadia Zitouna; Safa Romdhane; Ghaith Abdessalem; Cherine Charfeddine; Faouzi Maazoul; Ines Ouerteni; Yosr Hamdi; Anissa Zaouak; Ridha Mrad; Sonia Abdelhak; Lilia Romdhane
Journal:  Genes (Basel)       Date:  2021-11-19       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.